Literature DB >> 7592575

Tissue-specific rescue suggests that placental adenosine deaminase is important for fetal development in mice.

M R Blackburn1, M Wakamiya, C T Caskey, R E Kellems.   

Abstract

Adenosine deaminase (ADA, EC 3.5.4.4) is an essential enzyme of purine metabolism that is expressed at very high levels in the murine placenta where it accounts for over 95% of the ADA present at the fetal gestation site. We have recently shown that ADA-deficient fetuses, which also lack ADA in their adjoining placentas, die during late fetal development in association with profound purine metabolic disturbances and hepatocellular impairment. We have now investigated the potential importance of placental ADA by genetically restoring the enzyme to placentas of ADA-deficient fetuses. This genetic engineering strategy corrected most of the purine metabolic disturbances, prevented serious fetal liver damage, and rescued the fetuses from perinatal lethality. Our findings suggest that placental ADA is important for murine fetal development and illustrate a general strategy for the tissue specific correction of phenotypes associated with null mutations in mice.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7592575     DOI: 10.1074/jbc.270.41.23891

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  15 in total

1.  Adenosine deaminase deficiency increases thymic apoptosis and causes defective T cell receptor signaling.

Authors:  S G Apasov; M R Blackburn; R E Kellems; P T Smith; M V Sitkovsky
Journal:  J Clin Invest       Date:  2001-07       Impact factor: 14.808

Review 2.  Pathophysiology of glia in perinatal white matter injury.

Authors:  Stephen A Back; Paul A Rosenberg
Journal:  Glia       Date:  2014-03-31       Impact factor: 7.452

Review 3.  Purinergic signalling in the reproductive system in health and disease.

Authors:  Geoffrey Burnstock
Journal:  Purinergic Signal       Date:  2013-11-23       Impact factor: 3.765

Review 4.  Adenosine hypothesis of schizophrenia--opportunities for pharmacotherapy.

Authors:  Detlev Boison; Philipp Singer; Hai-Ying Shen; Joram Feldon; Benjamin K Yee
Journal:  Neuropharmacology       Date:  2011-02-17       Impact factor: 5.250

5.  Neonatal hepatic steatosis by disruption of the adenosine kinase gene.

Authors:  Detlev Boison; Louis Scheurer; Valérie Zumsteg; Thomas Rülicke; Piotr Litynski; Brian Fowler; Sebastian Brandner; Hanns Mohler
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-07       Impact factor: 11.205

6.  Elevated placental adenosine signaling contributes to the pathogenesis of preeclampsia.

Authors:  Takayuki Iriyama; Kaiqi Sun; Nicholas F Parchim; Jessica Li; Cheng Zhao; Anren Song; Laura A Hart; Sean C Blackwell; Baha M Sibai; Lee-Nien L Chan; Teh-Sheng Chan; M John Hicks; Michael R Blackburn; Rodney E Kellems; Yang Xia
Journal:  Circulation       Date:  2014-12-23       Impact factor: 29.690

Review 7.  Modulators of nucleoside metabolism in the therapy of brain diseases.

Authors:  Detlev Boison
Journal:  Curr Top Med Chem       Date:  2011       Impact factor: 3.295

8.  Transcription factor gene AP-2 gamma essential for early murine development.

Authors:  Uwe Werling; Hubert Schorle
Journal:  Mol Cell Biol       Date:  2002-05       Impact factor: 4.272

Review 9.  Use of transgenic mice model for understanding the placentation: towards clinical applications in human obstetrical pathologies?

Authors:  V Sapin; L Blanchon; A F Serre; D Lémery; B Dastugue; S J Ward
Journal:  Transgenic Res       Date:  2001-10       Impact factor: 2.788

10.  Neonatal bone marrow transplantation of ADA-deficient SCID mice results in immunologic reconstitution despite low levels of engraftment and an absence of selective donor T lymphoid expansion.

Authors:  Denise A Carbonaro; Xiangyang Jin; Daniel Cotoi; Tiejuan Mi; Xiao-Jin Yu; Dianne C Skelton; Frederick Dorey; Rodney E Kellems; Michael R Blackburn; Donald B Kohn
Journal:  Blood       Date:  2008-03-20       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.